Almirall meets 2025 guidance, delivering 12.4% net sales growth and continued pipeline progress

Our full-year financial results confirmed that we sustained a solid growth trajectory in 2025, meeting our full‑year guidance and underscoring our leadership in medical dermatology. We have delivered solid financial results, continued investment in innovation, and proved the strength of our dermatology‑focused strategy in Europe.

During 2025, we delivered net sales growth in 2025 of 12.4% exceeding €1bn (total of €1,108.1MM), revenue increase of 12.5% (total of €1,114.5 MM), and EBITDA growth of 20.9% (total of €232.9 MM) – in line with our guidance and sustained growth trajectory. This revenue growth further advances our leadership in medical dermatology driven by the strong performance of the European dermatology business (+25.6% YoY increase to a total of €608 MM).

Innovation remains central to our strategy. In 2025, we invested €138.1 million in R&D (12.5% of net sales), supporting a diversified pipeline focused on skin diseases with high unmet medical need. Progress across multiple clinical programs highlights our commitment to translating science into meaningful patient outcomes.

Looking ahead, we remain confident in our strategy and long‑term outlook. By combining commercial excellence, scientific rigor, and collaboration with the dermatology community, we continue to strengthen our leadership in medical dermatology—guided by our purpose of improving patients’ lives.